secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001213900-26-041604
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx appoints Microsoft Health COO Mary Varghese Presti to board
----------------------------------------------------------------------

- Mary Varghese Presti appointed independent director effective April 3, 2026; board expanded to 7 members.
- She serves on Audit Committee; receives $45k annual cash retainer plus $175k equity grant and $10k audit fee.
- Varghese Presti is Microsoft Corporate VP & COO, Health & Life Sciences, with 25+ years in healthcare/tech.
- CEO cites her experience in M&A, platform scaling, and commercialization as aligning with OptimizeRx strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390026041604/0001213900-26-041604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390026041604/ea0285473-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-041604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer